Gene Therapy for the Treatment of Chronic Stable Angina

Inclusion Criteria: * Age ≥ 21 years, but less than or equal to 75 years. * Stable chronic refractory angina classified as Canadian Cardiovascular Society (CCS) functional class II - IV * Left ventricular ejection fraction (LVEF) of ≥30% and ≤ 50%; * Clinical signs and symptoms of significant ischemia by treadmill test or Stress imaging (SPECT, Echo or CARDIAC MRI acceptable) * Subjects must be able to complete a minimum of 3 minutes, but no more than 10 minutes on a Modified Bruce treadmill protocol. * Patients on maximal medical therapy including at least 2 of the following (unless hemodynamic parameters or intolerance contraindicate their use):(a) Long acting nitrate, (b) Beta Blocker or (c) Calcium Channel Blocker (d) Ranolazine. Optimal medical regimen for each subject will be decided by the referring cardiologist or principal investigator. Patients must be on stable medical regimen for 30 days prior to enrollment. * Coronary angiogram within 1 year to confirm the presence of coronary disease which is not amenable to standard revascularization procedures. * Candidates must not be eligible for any other revascularization procedures. The participant and his/her coronary film must have been discussed with an independent cardiac surgeon and must have been denied for CABG or PTCA. Participants who are marginal or poor candidates for conventional revascularization will be considered eligible if the risks of performing a CABG or PTCA procedure outweigh the potential benefit an…